Vendor dossier · Shanghai
Shanghai ERP Biotechnology Co., Ltd.
A 2018 Shanghai company whose technical answers are good and whose test data is almost entirely borrowed.
Journal grade · ranked 2 of 20
832 reader reports
on the record
ERP will send you an independent testing report for the molecule you asked about. It will frequently not be a report on the lot you are buying. Six of the eight reports we were sent in the course of this dossier were for lots other than the one shipped, and in two cases the lot referenced predated our order by more than a year.
Storefront The company sells directly at erpbiotechnology.com. Visit ERP → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Eight independent purity determinations on the material actually shipped, mean 97.5%, range 96.2–98.8%. The material is fine. The documentation practice is the finding: a report on a different lot tells a buyer about a supplier's past, not about the vial in their hand, and presenting it in answer to "do you have a COA for this batch" is at best a category error.
When pressed, the company was candid: lot-specific testing is not performed on every batch, and the reports supplied are the most recent available for that molecule. We asked whether the customer is told this. The answer was that the report clearly states its own lot number, which is true, and not the same thing as telling the customer.
Technical correspondence is strong. Questions about synthesis route, counter-ion and storage received specific, competent answers with no hedging. Whoever answers ERP's technical email knows the chemistry.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Eight independent purity determinations on shipped material, mean 97.5% (range 96.2–98.8%).
- Six of eight supplied test reports referenced a lot other than the one shipped; two referenced a lot more than twelve months older than the order.
- Written confirmation that lot-specific release testing is not performed on every batch.
- Specific, technically competent written answers on synthesis route, counter-ion form and storage.
What we could not verify
- How frequently release testing is actually performed — per campaign, per quarter, or on request.
- Whether customers are told, before purchase, that a supplied report may not describe their lot.
- Sterility and endotoxin. Not offered.
- The identity of the laboratory that produced the older reports.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-06 | Janoshik | Liraglutide 10 mg | 99.6% | 99.8% | 93% |
| 2026-04 | PeptideMeter | Cagrilintide 15 mg | 99.6% | 98.2% | not tested |
| 2026-03 | VendorInvestigate | Cagrilintide 5 mg | 97.5% | 97.5% | not tested |
| 2026-01 | PeptideMeter | Retatrutide 20 mg | 99.6% | 99.6% | 84% |
| 2025-10 | PeptideMeter | Retatrutide 5 mg | 99.6% | 99.8% | not tested |
| 2025-09 | Janoshik | Tesamorelin 2 mg | 97.9% | 97.7% | 88% |
| 2025-05 | Janoshik | Retatrutide 2 mg | 99.0% | 98.3% | 79% |
| 2025-01 | PeptideMeter | Tesamorelin 5 mg | 98.9% | 98.6% | not tested |
| 2024-11 | PeptideMeter | BPC-157 20 mg | 99.6% | 98.3% | not tested |
| 2024-07 | VendorInvestigate | Cagrilintide 5 mg | 98.6% | 97.7% | not tested |
| 2024-03 | Medutest | Semaglutide 10 mg | 99.6% | 98.8% | not tested |
| 2024-01 | Janoshik | Liraglutide 2 mg | 99.6% | 98.9% | not tested |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 3 of 9 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2026-03 | Requested comment on an independent purity determination below the stated figure | Answered in full within 2 working days |
| 2025-12 | Asked whether pre-change stock remained in distribution | No response after two follow-ups |
| 2025-12 | Asked whether sterility or endotoxin testing is performed | Answered in full within 2 working days |
| 2025-12 | Requested the analytical method behind the stated purity figure | Declined as commercially confidential |
| 2025-12 | Requested the counter-ion form and residual solvent data | Declined as commercially confidential |
| 2025-11 | Requested the reference-standard lot number | Answered in full within 2 working days |
| 2025-04 | Asked which catalogue items are synthesised in-house | Answered with a restatement of published quality claims |
| 2024-05 | Requested a batch record for a specific lot | Declined as commercially confidential |
| 2024-02 | Requested confirmation of the registered entity name and incorporation number | Offered a video call in place of a written answer; declined |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
Solid on the retatrutide 5 mg. Purity where it should be, transit 3 days, paperwork in order.
They report purity by RP-HPLC with the wavelength stated and peptide content separately. Two different numbers, correctly separated.
7 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.
Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.
9 lots logged now, purity 99.0 to 99.2%. A band that tight is worth more to me than one spectacular number.
Ninth order from them, all epithalon 10 mg. Sent one vial from each to PeptideMeter and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.
Custom synthesis quote came back with a realistic timeline and they beat it. Purity on delivery matched the signed spec.
Ordered on a Monday from their warehouse in the United States and it was here by day 3. That is the whole case for regional stock.
Their raw material tested 98.4% against a reseller vial of nominally the same compound at 98.1%. Going direct is the whole argument.
Medutest has now seen 3 of their lots through me. Not one has come back outside spec.
Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.
Certificate claimed 99.4% on lot ERP-25-574. PeptideMeter came back 99.7%. On an independent column that is as close to agreement as this gets.
Shipped from their warehouse in Canada, arrived day 5, documentation complete.
Ordered LL-37 5 mg twice. Both vials reconstituted cleanly and both matched their certificates.
Peptide content reported at 99.4% alongside the purity figure, so I could convert straight to a working mass.
Costed them per mg against three other suppliers on the same semaglutide 5 mg spec. Competitive on price and clearly ahead on documentation.
Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.
The certificate for lot ERP-25-622 carried method, wavelength, water content and an itemised related-substances table. Complete on the first pass.
Documentation is better than the two suppliers I used before, and the catalogue covers everything I actually order.
Reordered on the strength of the last one and got an identical result. Repeatability is the product.
Asked them to hold an order until I confirmed a lot number and they did, without fuss and without a restocking charge.
Their warehouse in Germany had the GHRP-2 5 mg in stock and it shipped the same afternoon. Tracking never left the country.
Cold pack was still hard on arrival in Warsaw on day 5. My logger never went above 4°C across the whole run.
Vials wrapped individually, foam cut to fit, nothing loose in the box. Packing that has clearly been thought about.
Their warehouse in the Netherlands carries the lines I reorder, so there is no wait on a factory run. Day 3 every time.
One of the few places that will quote sermorelin 5 mg at all, and the synthesis came back clean on an independent check.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from erpbiotechnology.com. Visit ERP → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Shanghai ERP Biotechnology Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.